Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of ...

Given as neoadjuvant treatment, TAR-200 plus cetrelimab generated responses in patients with muscle-invasive bladder cancer.

ImmunityBio's stock has risen sharply this year. Read more on whether investors should look closely at shares or avoid the ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy profile of investigational ...

A gemcitabine intravesical releasing system ... alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer ...

Definitive treatment of muscle invasive bladder cancer depends on neoadjuvant chemotherapy and surgery ... Dr. Guarionex DeCastro presented the results of a phase II trial of intravesical cabazitaxel, ...

Furthermore, since chemotherapy and radiotherapy give disappointing ... However, we still don’t know whether SAHA can be used in bladder cancer treatment, especially by Intravesical administration for ...

When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cance ...

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible ...

Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...

Matthew Galsky, MD, discusses why some physicians were surprised at the positive outcomes of nivolumab trials in bladder ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...